In a time of market crisis, having a PhD in molecular biology on your research team looks like the smartest investment of all.
Antipodes Partners' healthcare sector head Nick Cameron is not your average investor trying to navigate volatile markets rocked by coronavirus fears, given his CV includes working on the development of a gene therapy for Parkinson's disease and experience in genetic engineering and viral factors.
Loading...
Robert writes on companies and markets. He is a former New York and Shanghai correspondent, and has worked in Hong Kong. Email Robert at robertguy@afr.com.au
